Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
E: jfletcher@lilly.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Stocks News & Analysis
markets
June 2025 US stock market outlook: Has the storm passed?
Be wary of the recent complacency; there’s turbulent water ahead before the skies clear.
markets
US stock market outlook: Where we see opportunities in Q2
A bear market in AI stocks leads to more attractive valuations.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,770.60 | 25.40 | -0.29% |
| CAC 40 | 7,765.11 | 10.79 | -0.14% |
| DAX 40 | 23,771.45 | 177.45 | -0.74% |
| Dow JONES (US) | 42,967.62 | 101.85 | 0.24% |
| FTSE 100 | 8,884.92 | 20.57 | 0.23% |
| HKSE | 23,854.82 | 180.56 | -0.75% |
| NASDAQ | 19,662.48 | 46.61 | 0.24% |
| Nikkei 225 | 37,799.27 | 373.82 | -0.98% |
| NZX 50 Index | 12,552.87 | 96.23 | -0.76% |
| S&P 500 | 6,045.26 | 23.02 | 0.38% |
| S&P/ASX 200 | 8,547.40 | 17.70 | -0.21% |
| SSE Composite Index | 3,380.06 | 22.59 | -0.66% |